Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating Range of VK2809 Doses for up to 52 Weeks; Data for Primary Endpoint Expected in First Half of 2023 SAN DIEGO, Jan. 9, 2023 ...
SAN DIEGO, March 26, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...
BHUBANESWAR: Chairman of 5T and Nabin Odisha VK Pandian on Friday directed officials concerned to stick to the December 31 deadline for completion of the inter-state bus terminal (ISBT) at Baramunda ...
SAN DIEGO, March 26, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...
Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback